Catalent, Inc. (CTLT)
Stock Price Chart
Key Info
| Market Cap | 15.47B |
| Revenue (ttm) | 3.09B |
| Net Income (ttm) | 220.70M |
| Shares Out | 164.51M |
| EPS (ttm) | 1.14 |
| PE Ratio | 82.47 |
| Forward PE | 40.65 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $94.02 |
| Previous Close | $93.40 |
| Change ($) | 0.62 |
| Change (%) | 0.66% |
| Day's Open | 93.80 |
| Day's Range | 92.21 - 94.30 |
| Day's Volume | 544,630 |
| 52-Week Range | 31.04 - 96.38 |
More Stats
| Market Cap | 15.47B |
| Enterprise Value | 17.53B |
| Earnings Date (est) | Nov 3, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 164.51M |
| Float | 162.53M |
| EPS (basic) | 1.16 |
| EPS (diluted) | 1.14 |
| FCF / Share | -0.17 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 1.21% |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.61M |
| Short Ratio | 0.59 |
| Short % of Float | 0.99% |
| Beta | 1.58 |
| PE Ratio | 82.47 |
| Forward PE | 40.65 |
| P/FCF Ratio | n/a |
| PS Ratio | 5.00 |
| PB Ratio | 5.30 |
| Revenue | 3.09B |
| Operating Income | 394.40M |
| Net Income | 220.70M |
| Free Cash Flow | -25.50M |
| Net Cash | -2.06B |
| Net Cash / Share | -12.55 |
| Gross Margin | 31.78% |
| Operating Margin | 12.75% |
| Profit Margin | 5.60% |
| FCF Margin | -0.82% |
| ROA | 3.67% |
| ROE | 7.62% |
| ROIC | 7.30% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,094 | 2,518 | 2,463 | 2,075 | 1,848 | 1,831 | 1,828 | 1,800 | 1,695 | 1,532 |
| Revenue Growth | 22.89% | 2.22% | 18.7% | 12.3% | 0.94% | 0.17% | 1.52% | 6.22% | 10.64% | - |
| Gross Profit | 983 | 805 | 753 | 655 | 588 | 615 | 599 | 569 | 559 | 502 |
| Operating Income | 394 | 274 | 269 | 234 | 218 | 260 | 241 | 204 | 198 | 186 |
| Net Income | 221 | 137 | 83.60 | 110 | 112 | 212 | 16.20 | -49.60 | -24.40 | -54.00 |
| Shares Outstanding | 155 | 146 | 133 | 125 | 125 | 124 | 117 | 117 | - | - |
| Earnings Per Share | 1.14 | 0.90 | 0.63 | 0.87 | 0.89 | 1.75 | 0.21 | -0.66 | -0.32 | -0.72 |
| EPS Growth | 26.67% | 42.86% | -27.59% | -2.25% | -49.14% | 733.33% | - | - | - | - |
| Operating Cash Flow | 440 | 248 | 375 | 300 | 155 | 172 | 178 | 138 | 87.90 | 99.70 |
| Capital Expenditures | -466 | -218 | -175 | -139 | -138 | -141 | -122 | -120 | -102 | -83.30 |
| Free Cash Flow | -25.50 | 30.10 | 200 | 160 | 17.60 | 30.80 | 56.80 | 18.10 | -14.10 | 16.40 |
| Cash & Equivalents | 953 | 345 | 410 | 288 | 132 | 151 | 74.40 | 106 | 139 | - |
| Total Debt | 3,018 | 2,959 | 2,721 | 2,080 | 1,861 | 1,881 | 2,711 | 2,692 | 2,684 | - |
| Net Cash / Debt | -2,065 | -2,614 | -2,311 | -1,791 | -1,729 | -1,730 | -2,636 | -2,585 | -2,545 | - |
| Assets | 7,777 | 6,184 | 4,531 | 3,454 | 3,091 | 3,138 | 3,090 | 2,950 | 3,139 | - |
| Liabilities | 4,271 | 3,896 | 3,444 | 2,731 | 2,455 | 2,504 | 3,462 | 3,360 | 3,490 | - |
| Book Value | 2,899 | 1,682 | 1,087 | 724 | 636 | 634 | -371 | -411 | -351 | - |
Company Profile
Company Details
| Full Name | Catalent, Inc. |
| Country | United States |
| Employees | 13,900 |
| CEO | John R. Chiminski |
Stock Information
| Ticker Symbol | CTLT |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: CTLT |
| IPO Date | July 31, 2014 |
Description
Catalent, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; and a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.